Protalix (PLX) Operating Margin

Public company logo of Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics is developing a plant-cell protein synthesis system for the treatment of rare pathologies. The operating margin trend shows that the current level is 29.80. High R&D potential and unique patents provide the company with a technological edge. The business is currently scaling sales of its approved enzyme drug through partnerships with pharma behemoths while introducing new molecules.

Protalix BioTherapeutics, Inc. (PLX): Operating Profit Margin from 07/04/2022 to 11/19/2026

Metric breakdowns and analytics for Protalix BioTherapeutics, Inc. (PLX)

Core merchandise of protalix.com

Operating margin measures the efficiency of the core business by determining the share of profit before taxes and interest relative to total revenue. This indicator allows for an assessment of internal process profitability and helps avoid overpaying for an asset. By analyzing the quarterly operating margin, an investor can gauge the stability of cash flows. For Protalix BioTherapeutics (PLX), this metric reflects a dependence on a single drug. A partnership with a global distributor helps stabilize margins within a single-product revenue structure.